{"id":388807,"date":"2020-11-25T21:38:05","date_gmt":"2020-11-26T02:38:05","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388807"},"modified":"2020-11-25T21:38:05","modified_gmt":"2020-11-26T02:38:05","slug":"senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/","title":{"rendered":"Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n TAIPEI<\/span> and SAN DIEGO<\/span>, Nov. 25, 2020<\/span> \/PRNewswire\/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has submitted multiple\u00a0Investigational New Drug<\/a>\u00a0(IND) applications to the\u00a0U.S. Food and Drug Administration<\/a>\u00a0(FDA) and Health Canada evaluating its investigational drug, CX-5461,\u00a0for the treatment of patients with solid tumors with BRCA2<\/i> or PALB2 <\/i>mutations. <\/p>\n

“This IND submission is a key milestone in the clinical development of CX-5461. In a phase I study conducted by Senhwa’s clinical partner, Canadian Cancer Trial Group (CCTG), CX-5461 demonstrated clinically meaningful and lasting benefits in patients with specific tumor biomarkers that were resistant to platinum and other chemotherapeutics. The US and Canada<\/span> clinical trials are being designed to further confirm the efficacy seen,” said Dr. John Soong<\/span>, Chief Medical Officer of Senhwa Biosciences. <\/p>\n

CX-5461 was recently named as a PCF-Pfizer Global Challenge Award recipient. Specifically, it will be used in combination with Pfizer’s PARP inhibitor (PARPi), Talazoparib, to explore the therapeutic potential in prostate cancer,\u00a0which is the second-leading cause of cancer death for\u00a0men<\/i>\u00a0in the United States<\/span>. In 2016, a recipient of the Stand Up to Cancer’s Dream Team Grant selected CX-5461 to study in their Phase I trial. This study’s clinical findings were featured in a spotlighted presentation at the 2019 annual San Antonio Breast Cancer Symposium\u00a0<\/i>(SABCS 2019). <\/i>Due to the DNA repair defect, BRCA1\/2<\/i> deficient tumor cells are more sensitive to PARPi through the mechanism of synthetic lethality. However, PARPi resistance is ubiquitous in clinic. More than 40% of BRCA1\/2<\/i>-deficient patients fail to respond to PARPi. <\/p>\n

“CX-5461 is a first-in-class G-quadruplex stabilizer within a novel class of therapy that accelerates dsDNA breaks and has proven human efficacy across certain tumor types. We believe CX-5461 has great potential as a therapeutic for patients who have developed resistance to PAPRi or other chemotherapies. This continues to be an unmet medical need in cancer treatment,” said Dr. Tai-Sen Soong<\/span>, CEO of Senhwa Biosciences.<\/p>\n

\n About CX-5461<\/b>\n <\/p>\n

CX-5461 is designed to stabilize DNA G-quadruplexes of cancer cells and leads to disruption of the cell’s replication fork. While acting in concert with Homologous Recombination (HR) pathway deficiency, such as BRCA1\/2 mutations, replication forks stall and cause DNA breaks, resulting in cancer cell death. CX-5461 in combination with Homologous Recombination Deficiency (HRD) tumors may be exploited through a synthetic lethality approach, targeting DNA repair defects in HRD tumors. <\/p>\n

\n About Senhwa Bioscience<\/b>\n <\/p>\n

Senhwa Biosciences, Inc. is a leading clinical-stage company focusing on developing first-in-class, next-generation DDR therapeutics for patients with unmet medical needs in oncology. Headquartered in Taiwan<\/span>, with an operational base in San Diego, California<\/span>, Senhwa is well-positioned to oversee the development of its compounds.<\/p>\n

Development is currently focused on two lead products Silmitasertib (CX-4945) and Pidnarulex (CX-5461) with novel mechanisms of action and for multiple indications. Clinical trials are ongoing in Australia<\/span>, Canada<\/span>, United States<\/span>, Korea, and Taiwan<\/span>, with more currently in development.\u00a0<\/p>\n

Visit\u00a0Senhwa Biosciences for more details: www.senhwabio.com<\/a><\/p>\n

\n \"Cision\" View original content:http:\/\/www.prnewswire.com\/news-releases\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations-301180879.html<\/a><\/p>\n

SOURCE Senhwa Biosciences, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire TAIPEI and SAN DIEGO, Nov. 25, 2020 \/PRNewswire\/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has submitted multiple\u00a0Investigational New Drug\u00a0(IND) applications to the\u00a0U.S. Food and Drug Administration\u00a0(FDA) and Health Canada evaluating its investigational drug, CX-5461,\u00a0for the treatment of patients with solid tumors with BRCA2 or PALB2 mutations. “This IND submission is a key milestone in the clinical development of CX-5461. In a phase I study conducted by Senhwa’s clinical partner, Canadian Cancer Trial Group (CCTG), CX-5461 demonstrated clinically meaningful and lasting benefits in patients with specific tumor biomarkers that were resistant to platinum and other chemotherapeutics. The US … <\/p>\n

Continue reading “Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388807","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSenhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire TAIPEI and SAN DIEGO, Nov. 25, 2020 \/PRNewswire\/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has submitted multiple\u00a0Investigational New Drug\u00a0(IND) applications to the\u00a0U.S. Food and Drug Administration\u00a0(FDA) and Health Canada evaluating its investigational drug, CX-5461,\u00a0for the treatment of patients with solid tumors with BRCA2 or PALB2 mutations. “This IND submission is a key milestone in the clinical development of CX-5461. In a phase I study conducted by Senhwa’s clinical partner, Canadian Cancer Trial Group (CCTG), CX-5461 demonstrated clinically meaningful and lasting benefits in patients with specific tumor biomarkers that were resistant to platinum and other chemotherapeutics. The US … Continue reading "Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-26T02:38:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK04455&sd=2020-11-25\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations\",\"datePublished\":\"2020-11-26T02:38:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\\\/\"},\"wordCount\":540,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK04455&sd=2020-11-25\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\\\/\",\"name\":\"Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK04455&sd=2020-11-25\",\"datePublished\":\"2020-11-26T02:38:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK04455&sd=2020-11-25\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=HK04455&sd=2020-11-25\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/","og_locale":"en_US","og_type":"article","og_title":"Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations - Market Newsdesk","og_description":"PR Newswire TAIPEI and SAN DIEGO, Nov. 25, 2020 \/PRNewswire\/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage biopharmaceutical company focused on next-generation DNA Damage Response (DDR) therapeutics for the treatment of cancer, today announced that it has submitted multiple\u00a0Investigational New Drug\u00a0(IND) applications to the\u00a0U.S. Food and Drug Administration\u00a0(FDA) and Health Canada evaluating its investigational drug, CX-5461,\u00a0for the treatment of patients with solid tumors with BRCA2 or PALB2 mutations. “This IND submission is a key milestone in the clinical development of CX-5461. In a phase I study conducted by Senhwa’s clinical partner, Canadian Cancer Trial Group (CCTG), CX-5461 demonstrated clinically meaningful and lasting benefits in patients with specific tumor biomarkers that were resistant to platinum and other chemotherapeutics. The US … Continue reading \"Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-26T02:38:05+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK04455&sd=2020-11-25","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations","datePublished":"2020-11-26T02:38:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/"},"wordCount":540,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK04455&sd=2020-11-25","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/","name":"Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK04455&sd=2020-11-25","datePublished":"2020-11-26T02:38:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK04455&sd=2020-11-25","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=HK04455&sd=2020-11-25"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/senhwa-announces-multiple-ind-application-submissions-to-us-fda-and-health-canada-for-the-treatment-of-solid-tumors-with-brca2-or-palb2-mutations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Senhwa Announces Multiple IND Application Submissions to US FDA and Health Canada for the Treatment of Solid Tumors with BRCA2 or PALB2 Mutations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388807"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388807\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}